Marker Therapeutics (NASDAQ:MRKR) Stock Price Down 4.5%

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s stock price fell 4.5% during mid-day trading on Wednesday . The stock traded as low as $3.64 and last traded at $3.79. 12,110 shares changed hands during mid-day trading, a decline of 43% from the average session volume of 21,098 shares. The stock had previously closed at $3.97.

Analyst Upgrades and Downgrades

Separately, LADENBURG THALM/SH SH assumed coverage on Marker Therapeutics in a research note on Tuesday, April 30th. They set a “buy” rating and a $11.00 price objective on the stock.

Marker Therapeutics Stock Down 4.5 %

The stock has a fifty day simple moving average of $4.66 and a two-hundred day simple moving average of $4.40.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.27) earnings per share for the quarter. The company had revenue of $1.24 million during the quarter. Equities research analysts expect that Marker Therapeutics, Inc. will post -1.64 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Marker Therapeutics stock. International Assets Investment Management LLC raised its stake in shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) by 1,000.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 11,000 shares of the company’s stock after purchasing an additional 10,000 shares during the period. International Assets Investment Management LLC owned 0.12% of Marker Therapeutics worth $60,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.